Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Brolucizumab · Beovu, ESBA-1008

Monoclonal antibody · Antagonist of vascular endothelial growth factor A (VEGF-A) (VEGFA) · developed by Novartis Pharms

Approved FDA, Oct 2019
NVS Developer
1 Registered trials

What is Brolucizumab?

Brolucizumab is a human antibody that binds the three major isoforms of VEGF-A, preventing VEGF-A from interacting with VEGFR-1 and VEGFR-2. By inhibiting VEGF-A it suppresses endothelial cell proliferation, neovascularization and vascular permeability. It is studied in neovascular age-related macular degeneration and diabetic macular edema.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Beovu, ESBA-1008, RTH-258
Drug type
Monoclonal antibody
Targets
vascular endothelial growth factor A (VEGF-A) (VEGFA)
Mechanism
Antagonist of vascular endothelial growth factor A (VEGF-A) (VEGFA)
Pathways
VEGFR-1 and VEGFR-2 signaling, endothelial cell proliferation, neovascularization, vascular permeability
Therapy area
Ophthalmology
Developer
Novartis Pharms Corp (NVS)
FDA status
Approved as Beovu (October 7, 2019), BLA761125 · FDA label
UNII
XSZ53G39H5

✅ FDA-approved uses

From the indications section of the FDA label (version of Oct 26, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04543331 N/A Neovascular Age-related Macular Degeneration (nAMD) Completed NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetic Macular Edema (DME)Neovascular Age-related Macular Degeneration (nAMD)

Other drugs acting on VEGFA

More from Novartis Pharms

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Brolucizumab

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.